These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 23347986)

  • 21. How much will Herceptin really cost? Balancing local and national priorities is not new.
    Dillon A; Littlejohns P
    BMJ; 2006 Dec; 333(7580):1219; discussion 1219-20. PubMed ID: 17158393
    [No Abstract]   [Full Text] [Related]  

  • 22. "It's the economy, stupid": strategies for improved cost containment in cancer treatment.
    Sleijfer S
    Clin Pharmacol Ther; 2014 Apr; 95(4):365-7. PubMed ID: 24646487
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Roche responds to the 'Herceptin or deception' article.
    Petersen S
    N Z Med J; 2006 Jul; 119(1237):U2069; author reply U2069. PubMed ID: 16862210
    [No Abstract]   [Full Text] [Related]  

  • 24. Patient demand and politics push Herceptin forward.
    Kondro W; Sibbald B
    CMAJ; 2005 Aug; 173(4):347-8. PubMed ID: 16103498
    [No Abstract]   [Full Text] [Related]  

  • 25. News feature: Costly US anticancer drugs pose problems for doctors and patients.
    Charatan F
    BMJ; 2008 Jul; 337(7662):a778. PubMed ID: 18625596
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Skipping for herceptin funds.
    Harrison J
    Nurs N Z; 2007 Nov; 13(10):4. PubMed ID: 18084962
    [No Abstract]   [Full Text] [Related]  

  • 27. [Cost-effectiveness of trastuzumab in the treatment of early stages breast cancer patients, in Portugal].
    Macedo A; Monteiro I; Andrade S; Cirrincione A; Ray J
    Acta Med Port; 2010; 23(3):475-82. PubMed ID: 20654267
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Accessibility to targeted oncology drugs in Slovenia and selected European countries.
    Kos M; Obradovic M; Mrhar A
    Eur J Cancer; 2008 Feb; 44(3):408-18. PubMed ID: 18155900
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Valuing end-of-life care in the United States: the case of new cancer drugs.
    Sorenson C
    Health Econ Policy Law; 2012 Oct; 7(4):411-30. PubMed ID: 23079300
    [TBL] [Abstract][Full Text] [Related]  

  • 30. NICE confirms advanced breast cancer drug is too expensive for NHS.
    White C
    BMJ; 2014 Aug; 349():g5078. PubMed ID: 25106642
    [No Abstract]   [Full Text] [Related]  

  • 31. Trastuzumab in breast cancer.
    Mastrianni DM
    N Engl J Med; 2006 Feb; 354(6):640-4; author reply 640-4. PubMed ID: 16470953
    [No Abstract]   [Full Text] [Related]  

  • 32. Should the cost of care for patients with glioblastoma influence treatment decisions?
    Dropcho EJ
    Continuum (Minneap Minn); 2012 Apr; 18(2):416-20. PubMed ID: 22810136
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Utilization of antineoplastic agents in Sweden and Europe].
    Wilking N; Jönsson B; Björn W
    Lakartidningen; 2010 Apr 21-27; 107(16):1075-80. PubMed ID: 20476705
    [No Abstract]   [Full Text] [Related]  

  • 34. Addressing rising health care costs--a view from the Congressional Budget Office.
    Orszag PR; Ellis P
    N Engl J Med; 2007 Nov; 357(19):1885-7. PubMed ID: 17989379
    [No Abstract]   [Full Text] [Related]  

  • 35. Cost-effective treatment options in first-line therapy for advanced breast cancer in Japan.
    Kondo M; Toi M
    Expert Rev Anticancer Ther; 2006 Feb; 6(2):197-204. PubMed ID: 16445372
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Human epidermal growth factor receptor 2 expression in early breast cancer patients: a Swiss cost-effectiveness analysis of different predictive assay strategies.
    Blank PR; Schwenkglenks M; Moch H; Szucs TD
    Breast Cancer Res Treat; 2010 Nov; 124(2):497-507. PubMed ID: 20364309
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Patients with cancer denied treatment with new expensive drugs].
    Linné T
    Lakartidningen; 2012 Jun 27-Jul 17; 109(26-28):1298. PubMed ID: 22852261
    [No Abstract]   [Full Text] [Related]  

  • 38. The cost of the newest cancer drugs.
    Van Duppen D; Avonts M
    Lancet; 2007 Jul; 370(9584):317-8. PubMed ID: 17662877
    [No Abstract]   [Full Text] [Related]  

  • 39. New "managed access" process for Cancer Drugs Fund to go ahead, NHS England confirms.
    Mayor S
    BMJ; 2016 Feb; 352():i1208. PubMed ID: 26926879
    [No Abstract]   [Full Text] [Related]  

  • 40. Grouping of molecularly targeted anti-cancer agents based on cost-effectiveness analysis.
    Tirelli U; Berretta M; Bearz A; Carbone A
    Eur Rev Med Pharmacol Sci; 2011 Nov; 15(11):1355-6. PubMed ID: 22195374
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.